CA3171917A1 - Compositions for treating respiratory tract infection and uses thereof - Google Patents

Compositions for treating respiratory tract infection and uses thereof Download PDF

Info

Publication number
CA3171917A1
CA3171917A1 CA3171917A CA3171917A CA3171917A1 CA 3171917 A1 CA3171917 A1 CA 3171917A1 CA 3171917 A CA3171917 A CA 3171917A CA 3171917 A CA3171917 A CA 3171917A CA 3171917 A1 CA3171917 A1 CA 3171917A1
Authority
CA
Canada
Prior art keywords
seq
peptide
group
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171917A
Other languages
English (en)
French (fr)
Inventor
Andrew GEARING
David KENLEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lateral IP Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900807A external-priority patent/AU2020900807A0/en
Application filed by Individual filed Critical Individual
Publication of CA3171917A1 publication Critical patent/CA3171917A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3171917A 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof Pending CA3171917A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2020900807 2020-03-16
AU2020900807A AU2020900807A0 (en) 2020-03-16 Compositions for treating respiratory tract infection and uses thereof
AU2020900818 2020-03-17
AU2020900818A AU2020900818A0 (en) 2020-03-17 Compositions for treating respiratory tract infection and uses thereof
AU2020904226 2020-11-16
AU2020904226A AU2020904226A0 (en) 2020-11-16 Compositions for treating respiratory tract infection and uses thereof
PCT/AU2021/050229 WO2021184062A1 (en) 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof

Publications (1)

Publication Number Publication Date
CA3171917A1 true CA3171917A1 (en) 2021-09-23

Family

ID=77767913

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171917A Pending CA3171917A1 (en) 2020-03-16 2021-03-16 Compositions for treating respiratory tract infection and uses thereof

Country Status (7)

Country Link
US (1) US20230256059A1 (https=)
EP (1) EP4121084A4 (https=)
JP (1) JP2023518376A (https=)
CN (1) CN115297882A (https=)
AU (1) AU2021237981A1 (https=)
CA (1) CA3171917A1 (https=)
WO (1) WO2021184062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021003531A1 (en) * 2019-07-09 2021-01-14 Lateral IP Pty Ltd Peptides and uses thereof
JP2024516327A (ja) * 2021-05-07 2024-04-12 ラテラル、ファーマ、プロプライエタリー、リミテッド 炎症性気道疾患を処置するための組成物及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20080333A0 (fi) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
BR112014013757A2 (pt) * 2011-12-09 2019-08-27 Metabolic Pharmaceuticals Pty Ltd método para tratar osteoartrite; método para tratar uma condição que envolve condrócitos funcionais insuficientes ou tecido cartilaginoso funcional insuficiente; e uso de um peptídeo
US9139626B2 (en) * 2012-09-13 2015-09-22 The Mitre Corporation Mitrecin A polypeptide with antimicrobial activity
SG11202006669RA (en) * 2018-01-15 2020-08-28 Lateral IP Pty Ltd Peptides and uses thereof
KR20220124196A (ko) * 2019-12-27 2022-09-13 레터럴 아이피 피티와이 리미티드 사이클릭 펩티드 수용체 란티오닌 신테타제 c-유사 단백질 (lancl) 및 이의 용도

Also Published As

Publication number Publication date
JP2023518376A (ja) 2023-05-01
CN115297882A (zh) 2022-11-04
AU2021237981A1 (en) 2022-10-13
EP4121084A4 (en) 2024-04-03
WO2021184062A1 (en) 2021-09-23
US20230256059A1 (en) 2023-08-17
EP4121084A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
ES3055494T3 (en) Treatment of respiratory diseases
CA3171917A1 (en) Compositions for treating respiratory tract infection and uses thereof
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
WO2020237322A1 (en) Peptides and uses thereof
ES2982915T3 (es) Interferones híbridos para tratar infecciones virales
US20250263435A1 (en) Peptide compositions capable of binding lanthionine synthetase c-like protein (lancl) and uses thereof
WO2022232885A1 (en) Compositions for treating inflammatory airway disease and uses thereof
WO2021253647A1 (zh) 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
US12492223B2 (en) Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방
CN108926707A (zh) Pf4的抗rsv应用
ES3002532T3 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US11161881B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
AU2006201655A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
KR20240095267A (ko) 비외막형 바이러스 감염의 치료에 사용하기 위한 변형된 트리펩타이드
CN111655251A (zh) 用于治疗鼻病毒的羟基苯甲酸的酯
WO2021202745A1 (en) Treatment of covid-19 with a sine compound
WO2006095433A1 (ja) ウシの消化器疾患治療剤
CN102526710A (zh) 一种治疗猪病毒病蛋白质组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250331

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250731

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102